Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01027884 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)
A Phase 3 study of Muscular Dystrophy, Duchenne and Ambulatory Care, sponsored by Santhera Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT01027884 is a Phase 3 study of Muscular Dystrophy, Duchenne and Ambulatory Care that has completed, run by Santhera Pharmaceuticals. The registered enrollment target is 65 participants, below the 91-participant average among 4 other Muscular Dystrophy, Duchenne trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT01027884, a Phase 3 study of Muscular Dystrophy, Duchenne and Ambulatory Care, has completed, sponsored by Santhera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this Phase III study was to assess the efficacy of idebenone on pulmonary function, motor function, muscle strength and quality of life in patients with DMD. Furthermore, the safety and tolerability of idebenone was assessed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Idebenone
Study Locations (20)
Other
- Dr. Günther Bernert, Prim. Univ. Doz. - Vienna
- University Hospitals Leuven- Children Hospital - Leuven
- Hôpital Roger Salengro, CHRU Lille - Lille
- Prof. Thomas Voit , MD, PhD - Paris
- Universitätsklinikum Essen, Zentrum für Kinderheikunde - Essen
- Universitätsklinik Freiburg Zentrum für Kinderheilkunde und Jugendmedizin - Freiburg im Breisgau
- Fondazione IRCCS "Eugenio Medea" - Bosisio Parini, Lecco
- Azienda Ospedaliera Niguarda Ca' Granda Centro Clinico Nemo - Milan
- Azienda Ospedaliera Universitaria della Seconda Università degli Studi di Napoli - Naples
- Hospital Universitario 12 de Octubre - Madrid
Texas
- University of Texas Southwestern Medical Center - Dallas
- Methodist Neurological Institute - Houston
California
- University of California Davis Medical Center - Sacramento
Colorado
- Children's Hospital Colorado - Aurora
Florida
- University of Florida - Gainesville
North Carolina
- Carolinas Medical Center, Neurosciences and Spine Institute - Charlotte
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Monroe Carell, Jr. Children's Hospital at Vanderbilt - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01027884
The ClinicalTrials.gov registry entry for NCT01027884 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 4 other Muscular Dystrophy, Duchenne trials with a reported enrollment target (29% lower). The listed sponsor is Santhera Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Muscular Dystrophy, Duchenne appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01027884 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT01027884 about?
NCT01027884 is a clinical study titled "Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)". The aim of this Phase III study was to assess the efficacy of idebenone on pulmonary function, motor function, muscle strength and quality of life in patients with DMD. Furthermore, the safety and tolerability of idebenone was assessed.
What is the current status of trial NCT01027884?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2009-07. Estimated completion is 2014-04.
What conditions does trial NCT01027884 study?
This clinical trial studies the following conditions: Muscular Dystrophy, Duchenne, Ambulatory Care.
What interventions are being tested in trial NCT01027884?
The interventions under investigation include: Placebo (DRUG), Idebenone (DRUG).
Who is sponsoring clinical trial NCT01027884?
This trial is sponsored by Santhera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01027884 being conducted?
This trial has 20 study locations across California, Colorado, Florida, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscular Dystrophy, Duchenne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
ACTIVE NOT RECRUITING · Phase 3
-
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.